A nerisopam és N-acetil metabolitjainak humán farmakokinetikai vizsgálata.

Translated title of the contribution: Human pharmacokinetic study of nerisopam and its n-acetyl metabolite

K. Róna, K. Ary, G. Renczes, B. Gachályi, G. Grézal, S. Drabant, M. Csörgö, I. Klebovich

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

It was established during the human phase I study of nerisopam, a new anxiolytic drug, that nerisopam (EGIS-6775) shows two, while N-acetyl metabolite (EGIS-7649) shows one compartmental pharmacokinetic behaviour. Acetylation of nerisopam is polymorph, so that volunteers belonging into slow or fast acetylating group show significantly different plasma concentration. Observed pharmacokinetic differences are primarily manifested in the absorption phase, and not in the elimination one. Accordingly, slow acetylators have higher nerisopam levels, while fast acetylators possess higher metabolite levels. Elimination phase is practically parallel for both compounds. At the same time, significant differences are found in the AUC and Cmax values. Nerisopam is rapidly absorbed, but N-acetyl metabolite is appeared especially fast in the blood. Our consideration is, that nerisopam undergoes significant "first-pass" metabolism process, the extent of which is different between the two acetylator phenotypes.

Original languageHungarian
Pages (from-to)65-71
Number of pages7
JournalActa Pharmaceutica Hungarica
Volume67
Issue number2-3
Publication statusPublished - Mar 1997

Fingerprint

Pharmacokinetics
Anti-Anxiety Agents
Acetylation
Area Under Curve
Nerisopam
Volunteers
Phenotype
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Róna, K., Ary, K., Renczes, G., Gachályi, B., Grézal, G., Drabant, S., ... Klebovich, I. (1997). A nerisopam és N-acetil metabolitjainak humán farmakokinetikai vizsgálata. Acta Pharmaceutica Hungarica, 67(2-3), 65-71.

A nerisopam és N-acetil metabolitjainak humán farmakokinetikai vizsgálata. / Róna, K.; Ary, K.; Renczes, G.; Gachályi, B.; Grézal, G.; Drabant, S.; Csörgö, M.; Klebovich, I.

In: Acta Pharmaceutica Hungarica, Vol. 67, No. 2-3, 03.1997, p. 65-71.

Research output: Contribution to journalArticle

Róna, K, Ary, K, Renczes, G, Gachályi, B, Grézal, G, Drabant, S, Csörgö, M & Klebovich, I 1997, 'A nerisopam és N-acetil metabolitjainak humán farmakokinetikai vizsgálata.', Acta Pharmaceutica Hungarica, vol. 67, no. 2-3, pp. 65-71.
Róna K, Ary K, Renczes G, Gachályi B, Grézal G, Drabant S et al. A nerisopam és N-acetil metabolitjainak humán farmakokinetikai vizsgálata. Acta Pharmaceutica Hungarica. 1997 Mar;67(2-3):65-71.
Róna, K. ; Ary, K. ; Renczes, G. ; Gachályi, B. ; Grézal, G. ; Drabant, S. ; Csörgö, M. ; Klebovich, I. / A nerisopam és N-acetil metabolitjainak humán farmakokinetikai vizsgálata. In: Acta Pharmaceutica Hungarica. 1997 ; Vol. 67, No. 2-3. pp. 65-71.
@article{06a398bab87845ff95fc6300fdb752f4,
title = "A nerisopam {\'e}s N-acetil metabolitjainak hum{\'a}n farmakokinetikai vizsg{\'a}lata.",
abstract = "It was established during the human phase I study of nerisopam, a new anxiolytic drug, that nerisopam (EGIS-6775) shows two, while N-acetyl metabolite (EGIS-7649) shows one compartmental pharmacokinetic behaviour. Acetylation of nerisopam is polymorph, so that volunteers belonging into slow or fast acetylating group show significantly different plasma concentration. Observed pharmacokinetic differences are primarily manifested in the absorption phase, and not in the elimination one. Accordingly, slow acetylators have higher nerisopam levels, while fast acetylators possess higher metabolite levels. Elimination phase is practically parallel for both compounds. At the same time, significant differences are found in the AUC and Cmax values. Nerisopam is rapidly absorbed, but N-acetyl metabolite is appeared especially fast in the blood. Our consideration is, that nerisopam undergoes significant {"}first-pass{"} metabolism process, the extent of which is different between the two acetylator phenotypes.",
author = "K. R{\'o}na and K. Ary and G. Renczes and B. Gach{\'a}lyi and G. Gr{\'e}zal and S. Drabant and M. Cs{\"o}rg{\"o} and I. Klebovich",
year = "1997",
month = "3",
language = "Hungarian",
volume = "67",
pages = "65--71",
journal = "Acta Pharmaceutica Hungarica",
issn = "0001-6659",
publisher = "Magyar Gyogyszereszeti Tarsasag",
number = "2-3",

}

TY - JOUR

T1 - A nerisopam és N-acetil metabolitjainak humán farmakokinetikai vizsgálata.

AU - Róna, K.

AU - Ary, K.

AU - Renczes, G.

AU - Gachályi, B.

AU - Grézal, G.

AU - Drabant, S.

AU - Csörgö, M.

AU - Klebovich, I.

PY - 1997/3

Y1 - 1997/3

N2 - It was established during the human phase I study of nerisopam, a new anxiolytic drug, that nerisopam (EGIS-6775) shows two, while N-acetyl metabolite (EGIS-7649) shows one compartmental pharmacokinetic behaviour. Acetylation of nerisopam is polymorph, so that volunteers belonging into slow or fast acetylating group show significantly different plasma concentration. Observed pharmacokinetic differences are primarily manifested in the absorption phase, and not in the elimination one. Accordingly, slow acetylators have higher nerisopam levels, while fast acetylators possess higher metabolite levels. Elimination phase is practically parallel for both compounds. At the same time, significant differences are found in the AUC and Cmax values. Nerisopam is rapidly absorbed, but N-acetyl metabolite is appeared especially fast in the blood. Our consideration is, that nerisopam undergoes significant "first-pass" metabolism process, the extent of which is different between the two acetylator phenotypes.

AB - It was established during the human phase I study of nerisopam, a new anxiolytic drug, that nerisopam (EGIS-6775) shows two, while N-acetyl metabolite (EGIS-7649) shows one compartmental pharmacokinetic behaviour. Acetylation of nerisopam is polymorph, so that volunteers belonging into slow or fast acetylating group show significantly different plasma concentration. Observed pharmacokinetic differences are primarily manifested in the absorption phase, and not in the elimination one. Accordingly, slow acetylators have higher nerisopam levels, while fast acetylators possess higher metabolite levels. Elimination phase is practically parallel for both compounds. At the same time, significant differences are found in the AUC and Cmax values. Nerisopam is rapidly absorbed, but N-acetyl metabolite is appeared especially fast in the blood. Our consideration is, that nerisopam undergoes significant "first-pass" metabolism process, the extent of which is different between the two acetylator phenotypes.

UR - http://www.scopus.com/inward/record.url?scp=0031087107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031087107&partnerID=8YFLogxK

M3 - Article

C2 - 9289938

VL - 67

SP - 65

EP - 71

JO - Acta Pharmaceutica Hungarica

JF - Acta Pharmaceutica Hungarica

SN - 0001-6659

IS - 2-3

ER -